제약회사의 현금흐름이 연구개발투자에 미치는 영향 -코스닥시장을 중심으로
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이문재 | - |
dc.contributor.author | 최만규 | - |
dc.date.accessioned | 2021-09-04T22:14:42Z | - |
dc.date.available | 2021-09-04T22:14:42Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1598-4877 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/95504 | - |
dc.description.abstract | The purpose of this study is to analyze the influence of the cash flow of pharmaceutical companies on R&D investment. 143 pharmaceutical companies listed in the KOSDAQ market from 2009 to 2013. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association (KLCA), and data related to stock price was extracted from KISVALUE-Ⅲ of NICE Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis. The summary of the findings and the interpretation of the significance of this are as follows: First, the current ratio (internal finance) had a positive influence on R&D investment. Second, the debt ratio (external finance) had a negative influence on R&D investment. The pharmaceutical company prefers internal funds to external funds due to the asymmetry of information in the loan markets. In other words, this shows why internal finances have a significant influence on R&D investment at pharmaceutical companies. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 한국콘텐츠학회 | - |
dc.title | 제약회사의 현금흐름이 연구개발투자에 미치는 영향 -코스닥시장을 중심으로 | - |
dc.title.alternative | Effect of Cash flow on the R&D investment of Pharmaceutical Companies - focused on KOSDAQ market | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 최만규 | - |
dc.identifier.doi | 10.5392/JKCA.2015.15.08.473 | - |
dc.identifier.bibliographicCitation | 한국콘텐츠학회 논문지, v.15, no.8, pp.473 - 480 | - |
dc.relation.isPartOf | 한국콘텐츠학회 논문지 | - |
dc.citation.title | 한국콘텐츠학회 논문지 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 473 | - |
dc.citation.endPage | 480 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002023551 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Pharmaceutical Companies | - |
dc.subject.keywordAuthor | R& | - |
dc.subject.keywordAuthor | D Investment | - |
dc.subject.keywordAuthor | Cash Flow | - |
dc.subject.keywordAuthor | Internal Finance | - |
dc.subject.keywordAuthor | External Finance | - |
dc.subject.keywordAuthor | 제약회사 | - |
dc.subject.keywordAuthor | 연구개발투자 | - |
dc.subject.keywordAuthor | 현금흐름 | - |
dc.subject.keywordAuthor | 내부금융 | - |
dc.subject.keywordAuthor | 외부금융 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.